论文信息 - Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial - 字舞流文

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

M. Ychou | E. Assenat | R. Guimbaud | O. Bouché | F. Ghiringhelli | R. Kianmanesh | L. Mineur | M. Rivoire | A. Adenis | T. Aparicio | S. Thézénas | E. Lopez-Crapez | E. François | M. Galais | M. Chauvenet | P. Houyau | M. Fonck | F. Khemissa | F. Audemar | A. Mercier-Blas | C. Jouffroy | René Adam